(Q37983258)

26 August 2017

title

Selection of chronic hepatitis B therapy with high barrier to resistance (English)

1 reference

26 August 2017

1 reference

1 reference

Robert Gish

1

1 reference

26 August 2017

Ji-Dong Jia

series ordinal

2

1 reference

26 August 2017

Stephen Locarnini

series ordinal

3

1 reference

26 August 2017

Fabien Zoulim

series ordinal

4

1 reference

26 August 2017

publication date

9 February 2012

1 reference

Lancet Infectious Diseases

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

341-353

1 reference

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Chronic hepatitis B: update 2009

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Risk and predictors of mortality associated with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Telbivudine versus lamivudine in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Mutation rate of the hepadnavirus genome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

The implications of drug resistance for strategies of combination antiviral chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Inhibition of hepatitis B virus polymerase by entecavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Hepatitis: Treatment failure in chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

In vivo antagonism with zidovudine plus stavudine combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Mutations affecting the replication capacity of the hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

In vitro characterization of viral fitness of therapy-resistant hepatitis B variants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Immune selection during chronic hepadnavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Hepatocyte turnover in transient and chronic hepadnavirus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Molecular virology of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Systematic review: combination therapies for treatment-naïve chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-beta-L-2',3'-dideoxy-3'-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Hepatitis B virus escape mutants induced by antiviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Entecavir for the treatment of chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

A combinatorial ledge: reverse transcriptase fidelity, total body viral burden, and the implications of multiple-drug HIV therapy for the evolution of antiviral resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Benefits and risks of combination therapy for hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

The Roadmap concept: using early on-treatment virologic responses to optimize long-term outcomes for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Hepatitis B virus resistance to adefovir in a nucleotide naive patient with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2811%2970314-0

7 January 2021

10.1016/S1473-3099(11)70314-0

Identifiers

DOI

1 reference

26 August 2017

1 reference